On May 5, 2025, Barclays analyst Matt Miksic announced a price target adjustment for DexCom (DXCM, Financial). The price target has been raised from the previous $90.00 to a new level of $93.00 USD. This change represents a 3.33% increase in the stock's price target.
The analyst has maintained DexCom's (DXCM, Financial) current rating at "Equal-Weight," indicating that expectations for the company's stock price align with market performance. Previously, DexCom (DXCM) held the same "Equal-Weight" rating.
Investors and market participants might find this adjustment as an indication of an anticipated positive outlook for DexCom's (DXCM, Financial) stock value, though the core rating remains unchanged. This adjustment reflects a revised forecast based on recent performance or anticipated developments within the company.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for DexCom Inc (DXCM, Financial) is $99.04 with a high estimate of $115.00 and a low estimate of $82.00. The average target implies an upside of 21.35% from the current price of $81.62. More detailed estimate data can be found on the DexCom Inc (DXCM) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, DexCom Inc's (DXCM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM, Financial) in one year is $167.04, suggesting a upside of 104.66% from the current price of $81.62. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the DexCom Inc (DXCM) Summary page.
